Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market


August 8, 2023

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting


June 29, 2023

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT


June 27, 2023

Cardiol Therapeutics Announces Year-End 2022 Update on Operations


March 29, 2023

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure


March 7, 2023

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis


January 17, 2023

Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent Pericarditis


December 12, 2022

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement


November 14, 2022

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis


November 7, 2022

2025 Cardiol Therapeutics. All right reserved.